Mass Spectrometry-Based Proteomics: Current Status and Potential Use in Clinical Chemistry : Clinical Chemistry and Laboratory Medicine

www.degruyter.com uses cookies, tags, and tracking settings to store information that help give you the very best browsing experience.
To understand more about cookies, tags, and tracking, see our Privacy Statement
I accept all cookies for the De Gruyter Online site

Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.


IMPACT FACTOR 2014: 2.707
Rank 6 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 0.741
Source Normalized Impact per Paper (SNIP) 2014: 1.011
Impact per Publication (IPP) 2014: 2.310

VolumeIssuePage

Issues

30,00 € / $42.00 / £23.00

Get Access to Full Text

Mass Spectrometry-Based Proteomics: Current Status and Potential Use in Clinical Chemistry

Pierre-Alain Binz / Denis F. Hochstrasser / Ron D. Appel

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 41, Issue 12, Pages 1540–1551, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2003.237, June 2005

Publication History

Published Online:
2005-06-01

Abstract

For some years now, scientists have been spending a lot of effort in developing methods to analyse and compare complex protein samples. One of the goals of such global analyses of what is known as proteomes is to discover specific protein markers–or fingerprints of protein markers−from various types of affected biological samples. Considering the battery of technologies currently available, mass spectrometry (MS) constitutes an essential tool in proteomics. We describe here the type of MS instrumentation that is currently dedicated to proteomics research. We also describe the major experimental workflows that are typically used in proteomics today, with a focus on those incorporating MS as a major analysis tool.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Melanie Hilario, Alexandros Kalousis, Julien Prados, and Pierre-Alain Binz
Drug Discovery Today: BIOSILICO, 2004, Volume 2, Number 5, Page 214
[2]
Dante Mantini, Francesca Petrucci, Damiana Pieragostino, Piero Del Boccio, Paolo Sacchetta, Giovanni Candiano, Gian Marco Ghiggeri, Alessandra Lugaresi, Giorgio Federici, Carmine Di Ilio, and Andrea Urbani
Journal of Proteomics, 2010, Volume 73, Number 3, Page 562
[3]
Domenico Milardi, Giuseppe Grande, Federica Vincenzoni, Irene Messana, Alfredo Pontecorvi, Laura De Marinis, Massimo Castagnola, and Riccardo Marana
Fertility and Sterility, 2012, Volume 97, Number 1, Page 67
[4]
F.-M. Schleif, T. Villmann, and B. Hammer
International Journal of Approximate Reasoning, 2008, Volume 47, Number 1, Page 4
[5]
Mario Plebani
Clinica Chimica Acta, 2005, Volume 357, Number 2, Page 113
[6]
Russell P. Newton, A.Gareth Brenton, Chris J. Smith, and Edward Dudley
Phytochemistry, 2004, Volume 65, Number 11, Page 1449
[7]
Tanja Werner and Dirk Haller
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2007, Volume 622, Number 1-2, Page 42
[8]
Judith Y.M.N. Engwegen, Marie-Christine W. Gast, Jan H.M. Schellens, and Jos H. Beijnen
Trends in Pharmacological Sciences, 2006, Volume 27, Number 5, Page 251
[9]
Han-Chang SUN, Ji-Yang ZHANG, Hui LIU, Wei ZHANG, Chang-Ming XU, Hai-Bin MA, Yun-Ping ZHU, and Hong-Wei XIE
PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2011, Volume 37, Number 12, Page 1278
[10]
Barbara Kossowska, Mirosława Ferens-Sieczkowska, Roman Gancarz, Ewa Passowicz-Muszyńska, and Renata Jankowska
Clinical Chemical Laboratory Medicine, 2005, Volume 43, Number 4
[11]
Florian Tribl, Helmut E Meyer, and Katrin Marcus
Expert Review of Proteomics, 2008, Volume 5, Number 2, Page 333
[12]
Wei-Wei Zhang
Pharmacogenomics, 2005, Volume 6, Number 6, Page 555
[13]
Ziad J. Sahab, Yan-Gao Man, Suzan M. Semaan, Robert G. Newcomer, Stephen W. Byers, and Qing-Xiang Amy Sang
Clinical & Experimental Metastasis, 2010, Volume 27, Number 7, Page 493
[14]
S.-J. Li, M. Peng, H. Li, B.-S. Liu, C. Wang, J.-R. Wu, Y.-X. Li, and R. Zeng
Nucleic Acids Research, 2009, Volume 37, Number Database, Page D907
[15]
Tadeusz J Kroczak, Jaroslaw Baran, Juliusz Pryjma, Maciej Siedlar, Iran Rashedi, Elizabeth Hernandez, Esteban Alberti, Subbareddy Maddika, and Marek Los
Expert Opinion on Therapeutic Targets, 2006, Volume 10, Number 2, Page 289
[16]
P. Schubert and D. V. Devine
ISBT Science Series, 2008, Volume 3, Number 1, Page 30
[17]
F. Tribl, K. Marcus, G. Bringmann, H. E. Meyer, M. Gerlach, and P. Riederer
Journal of Neural Transmission, 2006, Volume 113, Number 8, Page 1041

Comments (0)

Please log in or register to comment.